(VIANEWS) – RAMSAY GEN SANTE (GDS.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| RAMSAY GEN SANTE (GDS.PA) | €19.85 | 18.41% | 5.08% |
| CEGEDIM (CGM.PA) | €17.40 | 2.25% | 3.08% |
| UCB (UCB.BR) | €69.64 | 1.92% | 3.7% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. RAMSAY GEN SANTE (GDS.PA)
18.41% Forward Dividend Yield and 5.08% Return On Equity
Ramsay Générale de Santé SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology, as well as thoracic, vascular, and endovascular surgeries. The company was formerly known as Générale de Santé SA and changed its name to Ramsay Générale de Santé SA in December 2015. Ramsay Générale de Santé SA was founded in 1987 and is based in Paris, France. Ramsay Générale de Santé SA operates as a subsidiary of Ramsay Health Care Limited.
Earnings Per Share
As for profitability, RAMSAY GEN SANTE has a trailing twelve months EPS of €0.93.
PE Ratio
RAMSAY GEN SANTE has a trailing twelve months price to earnings ratio of 21.34. Meaning, the purchaser of the share is investing €21.34 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Volume
Today’s last reported volume for RAMSAY GEN SANTE is 314 which is 3.68% below its average volume of 326.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 2, 2014, the estimated forward annual dividend rate is 2.8 and the estimated forward annual dividend yield is 18.41%.
Volatility
RAMSAY GEN SANTE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.33%, a negative 0.61%, and a positive 1.74%.
RAMSAY GEN SANTE’s highest amplitude of average volatility was 1.66% (last week), 1.43% (last month), and 1.74% (last quarter).
More news about RAMSAY GEN SANTE.
2. CEGEDIM (CGM.PA)
2.25% Forward Dividend Yield and 3.08% Return On Equity
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals in France, other European countries, and internationally. It operates in two segments, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This segment also provides solutions for hosting, HR and payroll management outsourcing, electronic data exchange, and data processing services. The Healthcare Professionals division sells management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €0.8.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 21.75. Meaning, the purchaser of the share is investing €21.75 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 588.66M for the twelve trailing months.
More news about CEGEDIM.
3. UCB (UCB.BR)
1.92% Forward Dividend Yield and 3.7% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.7.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 40.96. Meaning, the purchaser of the share is investing €40.96 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.7%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 5.11B for the twelve trailing months.
Yearly Top and Bottom Value
UCB’s stock is valued at €69.64 at 21:30 EST, way below its 52-week high of €88.80 and higher than its 52-week low of €69.12.
More news about UCB.
